endocrine-treatment-of-transsexual-persons

Recommendations

Info

AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE 20 tests. Serum estradiol should be maintained at the mean daily level for pre-menopausal women (
TABLE 13. Masculinizing effects in FTM transsexual persons EFFECT ONSET a (months) MAXIMUM a (years) Skin oiliness/acne 1 – 6 1 – 2 Facial/body hair growth 6 – 12 4 – 5 Scalp hair loss 6 – 12 b Increased muscle mass/strength 6 – 12 2 – 5 Fat redistribution 1 – 6 2 – 5 Cessation of menses 2 – 6 c Clitoral enlargement 3 – 6 1 – 2 Vaginal atrophy 3 – 6 1 – 2 Deepening of voice 6 – 12 1 – 2 a Estimates represent clinical observations. See Refs 81, 92, 93. b Prevention and treatment as recommended for biological men. c Menorrhagia requires diagnosis and treatment by a gynecologist. TABLE 14. Feminizing effects in MTF transsexual persons EFFECT ONSET a 3.4. Values and Preferences Transsexual persons have very high expectations regarding the physical changes of hormone treatment and are aware that body changes can be enhanced by surgical procedures (e.g., breast, face, and body MAXIMUM a Redistribution of body fat 3 – 6 months 2 – 3 years Decrease in muscle mass and strength 3 – 6 months 1 – 2 years Softening of skin/decreased oiliness 3 – 6 months Unknown Decreased libido 1 – 3 months 3 – 6 months Decreased spontaneous erections 1 – 3 months 3 – 6 months Male sexual dysfunction Variable Variable Breast growth 3 – 6 months 2 – 3 years Decreased testicular volume 3 – 6 months 2 – 3 years Decreased sperm production Unknown > 3 years Decreased terminal hair growth 6 – 12 months > 3 years b Scalp hair No regrowth c Voice changes None d a Estimates represent clinical observations. See Refs 81, 92, 93. b Complete removal of male sexual hair requires electrolysis or laser treatment or both. c Familial scalp hair loss may occur if estrogens are stopped. d Treatment by speech pathologists for voice training is most effective. habitus). Clear expectations for the extent and timing of sex-hormone-induced changes may prevent the potential harm and expense of unnecessary procedures. ENDOCRINE TREATMENT OF TRANSSEXUAL PERSONS 21
Page 1 and 2: The Endocrine Society’s CLINICAL
Page 3 and 4: The Endocrine Society’s CLINICAL
Page 5 and 6: Abstract Objective: The aim was to
Page 7 and 8: 4.4. We suggest that bone mineral d
Page 9 and 10: TABLE 1. Definitions of terms used
Page 11 and 12: TABLE 2. DSM-IV-TR diagnostic crite
Page 13 and 14: TABLE 4. Hormone therapy for adults
Page 15 and 16: All referred subjects who satisfy e
Page 17 and 18: TABLE 6. Description of Tanner stag
Page 19 and 20: TABLE 9. Protocol induction of pube
Page 21: TABLE 12. Hormone regimens in the t
Page 25 and 26: Recommendation 4.2. We suggest moni
Page 27 and 28: guidelines for prostatic disease an
Page 29 and 30: Sex reassignment surgeries availabl
Page 31 and 32: 28. Meyer 3rd WJ, Bockting W, Cohen
Page 33 and 34: an endocrine society clinical pract
Page 35 and 36: 139. Miller N, Bedard YC, Cooter NB
Page 37 and 38: THE ENDOCRINE SOCIETY GUIDELINE ORD
Page 39 and 40: Commercial Reprint Information For

endocrine-treatment-of-transsexual-persons

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?